


















922Evaluation of Oral Beclomethasone Dipropionate
for Prevention of Acute Graft-versus-Host Disease
Paul J. Martin,1,2 Terry Furlong,1 Scott D. Rowley,3 Steven A. Pergam,1,2,4 Michele Lloid,1
Mark M. Schubert,1,5 Kevin J. Horgan,6 Barry E. Storer1,7Results from two randomized trials have shown that oral beclomethasone dipropionate (BDP) is effective for
treatment of acute gastrointestinal graft-versus-host disease. Here, we report results of a double-blind, ran-
domized placebo-controlled phase II study designed to test the hypothesis that acute graft-versus-host dis-
ease could be prevented by administration of oral BDP, beginning before hematopoietic cell transplantation
and continuing until day 75 after hematopoietic cell transplantation after myeloablative conditioning. Study
drug (BDP or placebo) was administered as 1-mg immediate-release formulation plus 1-mg delayed-
release formulation orally four times daily. According to the primary endpoint, systemic glucocorticoid treat-
ment for graft-versus-host disease was given to 60 of the 92 participants (65%) in the BDP arm, versus 31 of
46 participants (67%) in the placebo arm. The secondary efficacy endpoints showed no statistically significant
differences between the two arms. The proportion of participants who took at least 90% of the prescribed
study drug during the first 4 weeks after hematopoietic cell transplantation was 54% overall. Lower severity
of mucositis strongly correlated with higher adherence to the schedule of study drug administration. Incon-
sistent adherence related to mucositis during recovery after myeloablative conditioning may have obscured
a beneficial therapeutic effect in the current study.
Biol Blood Marrow Transplant 18: 922-929 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Hematopoietic cell transplantation, Acute graft-versus-host disease, Prevention,
GlucocorticoidsINTRODUCTION
Highly potent, topically active glucocorticoids such
as beclomethasone dipropionate (BDP) have long been
used for treatment of inflammatory diseases of the intes-
tinal tract, respiratory tract, and skin [1-3]. After oral
administration for treatment of intestinal inflam-
mation, BDP is rapidly hydrolyzed in both luminal
fluid and in mucosal cells. BDP is highly susceptible to1Divisions of Clinical Research, Fred Hutchinson
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6/j.bbmt.2011.11.010first-pass metabolism in the liver [4,5], is protein-
bound, and has a rapid disposition, thereby limiting
systemic effects. For treatment of intestinal mucosal in-
flammatory diseases, the retention of a topical glucocor-
ticoid, such as BDP, and its active metabolites in the
mucosa, with its reduced systemic bioavailability, offer
major therapeutic advantages over systemic glucocorti-
coids such as prednisone andmethylprednisolone,which
have well-recognized systemic adverse effects [6,7].
Recent experience at our center has shown that
60% to 70% of patients require systemic steroid ther-
apy for acute graft-versus-host disease (aGVHD) after
allogeneic hematopoietic cell transplantation (HCT)
with a myeloablative conditioning regimen. Results
of two previous randomized clinical trials indicated
that the combination of oral BDP plus a 10-day course
of prednisone (1 mg/kg/day) followed by a rapid 7-day
taper was more effective than prednisone alone for
initial treatment of grade II gastrointestinal GVHD
[8,9]. These studies are also the only prospective,
randomized clinical trials to suggest a survival ad-
vantage for a treatment of gastrointestinal GVHD.
Although prior studies evaluating prophylactic
systemic glucocorticoids after allogeneic bone marrow
transplantation have yielded inconsistent results, the
data from the two randomized BDPGVHD treatment
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effective in preventing aGVHD. Here, we report
results of a double-blind, randomized placebo-
controlled phase II study designed to test the hypoth-
esis that prophylactic administration of oral BDP,
beginning before transplantation and continuing until
day 75 after transplantation, would both prevent
aGVHD and also reduce its severity when it occurred.
METHODS
Patients
Patients who had allogeneic HCT with marrow
or growth factor-mobilized blood cells from HLA-A,
-B, -C, -DRB1, and HLA-DQB1 allele matched or
single allele or antigenmismatched relatedor unrelated
donors after a myeloablative conditioning regimen
(.800 cGy total-body irradiation [TBI] and cyclo-
phosphamide or high-dose busulfan and cyclophos-
phamide) were eligible for this study. Patients who
had transplantation with cord blood cells and those
who were enrolled in studies that involved depletion
of T cells from the graft or administration of T cell-
depleting antibodies before transplantation were
excluded. Patients with body weight\35 kg were also
excluded because lower-dose formulations of the study
drug were not available. All participants gave informed
consent as documented with the use of forms approved
by institutional review committees at the Fred Hutch-
inson Cancer Research Center and Hackensack Uni-
versity Medical Center.
Treatment
All participants received a standard regimen of
methotrexate and tacrolimus after transplantation
as prophylaxis against aGVHD [10]. Methotrexate
was given at 15 mg/m2 on day 1 after HCT and
10 mg/m2 on days 3, 6, and 11. Blinded study drug
(BDP or placebo) was manufactured by Soligenix, Inc.
(Princeton, NJ) and administered under IND 77,025
(P.J.M., sponsor-investigator) as 1-mg immediate-
release formulation plus 1-mgdelayed-release formula-
tion orally four times daily. Administration of the study
drug began at the start of the conditioning regimen and
continued through day 75 after transplantation.
Patients who were not able to ingest the study drug
because of mucositis continued their participation in
the study. Administration of the study drug continued
during systemic immunosuppressive treatment for
aGVHD, but administration of the study drug was dis-
continued if open-label oral BDP or budesonide was
administered to treat GVHD. Institutional standards
were used for antibacterial and antifungal prophylaxis.
Endpoints
The primary prespecified endpoint of the study
was development of aGVHD with severity sufficientto require systemic immunosuppressive treatment on
or before day 90 after transplantation such as: (1) pred-
nisone or its equivalent at $1 mg/kg/day, (2) systemic
immunosuppressive agents other than those in the
GVHD prophylactic regimen in lieu of high-dose
glucocorticoids, or (3) substitution of one calcineurin
inhibitor for the other in the GVHD prophylactic
regimen in order to treat overt GVHD. The following
actions were not considered as an indication of
aGVHD with severity sufficient to require systemic
immunosuppressive treatment: (1) administration of
high-dose glucocorticoids for indications other than
aGVHD, (2) substitution of one calcineurin inhibitor
for another in the GVHD prophylactic regimen in
order to manage toxicity, (3) increase in the dose of
the calcineurin inhibitor originally prescribed for
GVHD prophylaxis in order to suppress overt mani-
festations of aGVHD. For purposes of the primary
endpoint, extracorporeal photopheresis was consid-
ered as systemic immunosuppressive treatment, but
administration of psoralen andUV irradiation was not.
Secondary prespecified endpoints included (1)
cumulative glucocorticoid dose (measured as predni-
sone equivalents) per kg body weight during the first
75 days after transplantation; (2) peak and average
skin, liver, and gut morbidity stages and overall grades
[11] to day90 after transplantation; (3) average aGVHD
index score [12] to day 90 after transplantation; (4)
cumulative incidence of systemic immunosuppressive
treatment for aGVHDat any timeafter transplantation,
including extracorporeal photopheresis; (5) cumulative
incidence of topical therapy for aGVHD, including
psoralen and UV irradiation, hydrocortisone cream,
topical tacrolimus, oral BDP, or oral dexamethasone
rinses, (6) cumulative incidence of biopsy-proven gas-
trointestinal GVHD; (7) proportion of patients with
grade IIa GVHD, defined as stage I gastrointestinal in-
volvement with stage 0-2 skin involvement and no liver
involvement; (8) proportions of patients with grades
IIb-IVGVHD, with grade IIb GVHD defined as stage
3 skin involvement or stage 1 liver involvement with or
without stage 1 gastrointestinal involvement; (9) cumu-
lative incidence of chronicGVHD(cGVHD) requiring
systemic immunosuppressive treatment; (10)number of
days in the hospital during the first 90 days after trans-
plantation; (11) nonrelapse mortality; (12) overall sur-
vival; (13) survival at 200 days after transplantation;
and (14) survival without recurrent malignancy. In the
assessment of the aGVHD index score [12], parenteral
nutrition was employed as a surrogate for oral caloric
intake\40% of requirements.
Statistics
For purposes of sample size estimation, we
assumed that 60% of the participants in the placebo
arm would require systemic glucocorticoid treatment
for aGVHD. The trial was designed to provide 80%
Randomization
Allocated to BDP (N = 93)
Received allocated intervention (N = 92)
Did not receive allocated intervention (N = 1)
Reason: cardiac failure and death before
transplantation 
Allocated to placebo (N = 47)
Received allocated intervention (N = 46)
Did not receive allocated intervention (N = 1)
Reason: HCT deferred because of
transaminase elevation 
Continued BDP to day 75 (N = 37)
Discontinued BDP before day 75 (N = 55)
Reasons: GVHD (N = 50)
Patient choice (N = 2)
Intubation (N = 2)
Death (N = 1)
Continued placebo to day 75 (N = 15)
Discontinued placebo before day 75 (N = 31)
Reasons: GVHD (N = 27)
Patient choice (N = 1)
Bowel obstruction (N = 1)
Recurrent malignancy (N = 2)
Figure 1. Randomization and subsequent outcomes.
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the incidence of aGVHD requiring systemic immuno-
suppressive treatment between the oral BDP arm and
the placebo arm: this effect size was based on the out-
comes of the previous prospective treatment of grade
IIa acute gastrointestinal GVHD studies with oral
BDP. We surmised that grade IIa GVHD might be
largely eliminated by prophylactic administration of
BDP. Based on historical results from our center, we
estimated the frequency of grade IIa GVHD at
approximately 25%. A 2:1 randomization between
oral BDP and placebo was selected in order to allow
more robust estimation of the effect size for a variety
of potential endpoints that could be considered for
subsequent trials. With these nominal design parame-
ters, we planned to evaluate 92 participants in the oral
BDP arm and 46 participants in the placebo arm. An
interim analysis was conducted after 69 patients were
enrolled, with a plan to end the trial if the probability
of rejecting the null hypothesis had been\33%. This
criterion was not met, and the remaining patients were
accrued as originally planned.
The primary endpoint was analyzed as a binomial
outcome with differences evaluated by the unadjusted
X2 test with stratification according to donor type (re-
lated versus unrelated) and pretransplantation risk cat-
egory (chronic myeloid leukemia in chronic phase,
refractory anemia without excess blasts or other hema-
tologic malignancy in remission versus more advanced
malignancy). Other endpoints were evaluated by X2
test, Student’s t-test, Wilcoxon rank-sum test, or log-
rank test as appropriate, with no adjustment to the
computed significance level to account for the interim
analysis. Results were analyzed with data available as of
September 15, 2010.
RESULTS
Enrollment and Patient Characteristics
Between August 14, 2007 and April 14, 2010, 140
participants ranging from 8 to 63 years of age wererandomized, 93 to the BDP arm and 47 to the placebo
arm (Figure 1). One patient in the BDP arm developed
cardiac failure and died before the transplantation, and
one patient in the placebo arm was withdrawn from the
study when the transplantation was deferred because of
severe serumalanine aminotransferaseelevation after ad-
ministration of cyclophosphamide. Outcomes in the re-
maining 92 participants in the BDP arm and 46 patients
in the placebo arm are summarized in the information to
follow. Ten participants were enrolled at Hackensack
University Medical Center, and 128 were enrolled at
the Fred Hutchinson Cancer Research Center.
With one exception, characteristics of participants
in the two arms of the study were well balanced (Table
1). In the BDP arm, 46 of the 92 participants (50%) re-
ceived a pretransplantation conditioning regimen that
included TBI, compared with 15 of 46 participants
(33%) in the placebo arm.
Adherence with study drug administration during
the first 4 weeks after transplantation was similar in
the two arms but was less consistent than anticipated.
The mean adherence during the week before HCT
was 94%, declined to 88% and 65% during the first
and second weeks after HCT, respectively, and then
recovered to 79% and 91% during the third and fourth
weeks, respectively. The proportion of participants
who took at least 80% of the prescribed study drug
during the first 4 weeks after HCT appeared to be
somewhat lower in the BDP arm (62%) than in the
placebo arm (72%), but this difference was not statisti-
cally significant (P 5 .26). The proportion of partici-
pants who took at least 90% of the prescribed study
drug during the first 4 weeks after HCT was 53% in
the BDP arm and 57% in the placebo arm.
In the BDP arm, 37 of the 92 participants (40%)
took the study drug until day 75 after transplantation
as planned, compared with 15 of the 46 participants
(33%) in the placebo arm (P 5 .38). As shown in
Figure 1, reasons for discontinuation of study drug
administration before day 75 included systemic treat-
ment for aGVHD, patient choice, intubation, bowel
Table 1. Characteristics of Patients, According to Study Arm
Characteristic
BDP Placebo
N 5 92 N 5 46
Patient age, median years (range) 44 (8-63) 47 (12-62)
Diagnosis at transplantation, N (%)
Acute myeloid leukemia 42 (46) 15 (33)
Acute lymphoblastic leukemia 23 (25) 8 (17)
Chronic myeloid leukemia 6 (7) 7 (15)
Myelodysplastic neoplasms
or myeloproliferative syndromes
19 (21) 15 (33)
Other 2 (2) 1 (2)
Pretransplantation risk category, N (%)
Low or intermediate 78 (85) 40 (87)
High 14 (15) 6 (13)
Donor/patient gender, N (%)
Female/male 24 (26) 14 (30)
Other 68 (74) 32 (70)
High-intensity conditioning regimens, N (%)
Cyclophosphamide and
total body irradiation
46 (50) 15 (33)
Busulfan and cyclophosphamide 46 (50) 31 (67)
HLA-matching and donor type, N (%)
HLA-identical related 33 (36) 15 (33)
HLA-mismatched related 2 (2) 0 (0)
HLA-matched unrelated 43 (47) 25 (54)
HLA-mismatched unrelated 14 (15) 6 (13)
Type of graft, N (%)
Bone marrow 23 (25) 12 (26)
G-CSF-mobilized blood cells 69 (75) 34 (74)
Mean percent study drug taken through
week 4 after transplantation
80 82
Median percent study drug taken through
week 4 after transplantation
92 93
$80% adherence through week 4 after
transplantation, N (%)
57 (62) 33 (72)
$90% adherence through week 4 after
transplantation, N (%)
49 (53) 26 (57)
G-CSF indicates granulocyte colony stimulating factor.
Table 2. Efficacy Endpoints, According to Study Arm
Endpoint
BDP Placebo
P ValueN 5 92 N 5 46
Systemic treatment for acute GVHD
before day 90, N (%)
60 (65) 31 (67) .80
Cumulative mg/kg prednisone-
equivalent systemic glucocorticoid
dose to day 75, mean (SD)a
33.1 (23.3) 37.0 (27.1) .47
Peak skin morbidity score (SD) 1.13 (1.13) 1.26 (1.10) .52
Average weekly skin morbidity
score (SD)
0.30 (0.42) 0.27 (0.36) .68
Peak liver morbidity score (SD) 0.42 (0.93) 0.26 (0.65) .29
Average weekly liver morbidity
score (SD)
0.11 (0.31) 0.04 (0.12) .15
Peak weekly gut morbidity score (SD) 1.93 (1.07) 1.93 (1.06) .99
Average weekly gut morbidity
score (SD)
0.63 (0.36) 0.71 (0.33) .25
Peak weekly gut morbidity score after
day 21 (SD)
1.39 (1.07) 1.41 (0.97) .91
Average weekly gut morbidity score
after day 21 (SD)
0.47 (0.48) 0.59 (0.50) .16
Peak overall morbidity score,
mean (SD)
2.54 (0.62) 2.54 (0.59) .99
Average weekly overall morbidity
score, mean (SD)
1.22 (0.53) 1.36 (0.46) .14
Peak GVHD grade, N (%) .50
0-1 31 (34) 15 (33)
IIa 41 (45) 17 (37)
IIb-IV 20 (22) 14 (30)
Average weekly GVHD activity index,
mean (SD)
22.0 (13.1) 21.7 (11.2) .89
aFor GVHD, not including steroid treatment for other indications.
Table 3. Efficacy and Safety Outcomes Assessed as Hazard
Ratios, According to Study Arm
Outcome
Events
HR 95% CI P ValueBDP Placebo
Efficacy
Systemic treatment for acute
GVHDa
61 31 0.92 (0.6-1.4) .69
Gastrointestinal GVHD proven
by biopsya
44 18 1.26 (0.7-2.2) .40
Topical treatment for acute
GVHDa
58 31 0.89 (0.6-1.4) .60
Secondary systemic treatment for
GVHDa
8 6 0.65 (0.2-1.9) .43
Safety
CMV viremia or diseasea 23 12 0.93 (0.5-1.9) .84
Invasive yeast or mold infectiona 1 1 0.50 (0.0-7.9) .62
Chronic GVHD requiring systemic
treatmenta
31 13 1.05 (0.6-2.0) .87
Death without recurrent
malignancy
10 3 1.60 (0.4-5.8) .46
Recurrent malignancy 19 12 0.77 (0.4-1.6) .48
Death from any cause 22 11 0.95 (0.5-2.0) .89
Death or recurrent malignancy 29 15 0.93 (0.5-1.7) .83
CMV indicates cytomegalovirus; HR, hazard ratio.
aWithdrawal from follow-up or recurrent malignancy treated as com-
peting event.
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statistically significant differences between the two
study arms in the proportion of participants with pre-
mature discontinuation or in the distribution of causes.
Assessment of Efficacy
Systemic glucocorticoid treatment for GVHDwas
given to 60 participants (65%) in the BDP arm, com-
pared with 31 of 46 participants (67%) in the placebo
arm (P 5 .80) (Table 2). The secondary efficacy
endpoints also showed no statistically significant
differences between the two arms. These included cu-
mulative prednisone-equivalent glucocorticoid dose
from the day of transplantation to day 75 after trans-
plantation, peak and average weekly morbidity scores
in the skin, liver, and gastrointestinal tract, overall
morbidity score, peak GVHD grade, and average
weekly GVHD activity index.
Efficacy outcomes assessed as hazard ratios showed
no statistically significant differences between the
two arms (Table 3). The hazard ratio of systemic treat-
ment for acute GVHD in the BDP arm compared with
the placebo arm was 0.92 (95% confidence interval
[CI], 0.6-1.4; P5 .69). Likewise, no statistically signif-
icant differences were observed in the hazards of
gastrointestinal GVHD proven by biopsy, topicaltreatment for cutaneous or gastrointestinal GVHD,
or secondary systemic treatment for GVHD. Results
were similar when the analysis was adjusted for the
imbalanced use of TBI between the two arms (data
not shown).
The cumulative incidence of grades IIa-IVGVHD



















































































































Figure 2. Cumulative incidence of grades IIa-IV GVHD (top), grades
IIb-IV GVHD (middle), and grades III-IV GVHD (bottom). Grade IIa
GVHD is defined as gastrointestinal involvement with\1,000-mL stool
volume per day,\50% of body surface affected by rash, and serum total
bilirubin concentration\2.0 mg/dL. Grade IIb GVHD is defined as gas-
trointestinal involvement with\1,000 mL stool volume per day, with
more than 50% of body surface affected by rash or total serum bilirubin
concentration between 2.0 and 2.9 mg/dL.
Table 4. Gastrointestinal Adverse Events, According to
Study Arma
Adverse Event, N (%)
BDP Placebo
P ValueN 5 92 N 5 46
Oral infection 3 (3) 3 (7) .37
GI infection (any) 22 (24) 14 (30) .41
CMV enteritis 2 (2) 3 (7) .20
C. difficile 16 (17) 10 (22) .54
Other viral infection 2 (2) 1 (2) .99
Yeast or mold 0 (0) 0 (0)
Other 3 (3) 0 (0) .22
Esophagitis 8 (9) 3 (7) .67
Gastritis 2 (2) 0 (0) .32
Enteritis 0 (0) 0 (0)
Typhlitis 1 (1) 0 (0) .48
Colitis 0 (0) 1 (2) .15
GI hemorrhage 2 (2) 1 (2) .99
GI ulceration or erosion 5 (5) 0 (0) .11
Ileus 1 (0) 0 (0) .48
CMV indicates cytomegalovirus; GI, gastronitestinal.
aNumbers of patients with at least one episode; excludes two patients
who withdrew before transplantation.
926 Biol Blood Marrow Transplant 18:922-929, 2012P. J. Martin et al.57%-76%) in the BDP arm and 67% (95% CI,
54%-81%) in the placebo arm (Figure 2). The cumu-
lative incidence of grades IIb-IV GVHD at day 100
after transplantation was 22% (95% CI, 13%-30%)
in the BDP arm and 30% (95% CI, 17%-44%)
in the placebo arm. The cumulative incidence of
grades III-IV GVHD was 7% (95% CI, 1%-12%) in
the BDP arm and 9% (95% CI, 1%-17%) in the
placebo arm.Assessment of Safety
A variety of adverse outcomes assessed as hazard
ratios showed no statistically significant differences
between the two arms (Table 3). These included the
hazards of cytomegalovirus and invasive yeast or
mold infection, cGVHD, death without recurrent ma-
lignancy, recurrent malignancy, death from any cause,
and the composite of death or recurrent malignancy.
Likewise, the incidence of gastrointestinal adverse
events showed no statistically significant differences
between the two arms (Table 4). Gastrointestinal in-
fection was diagnosed in 22 participants (24%) in the
BDP arm, compared with 14 participants (30%) in
the placebo arm (P 5 .41). Other gastrointestinal
adverse events occurred infrequently.
Gastrointestinal ulceration or erosion was diag-
nosed by endoscopy in five participants who developed
anorexia, nausea, or vomiting, all in the BDP arm. Four
of the five patients with upper gastrointestinal
ulceration or erosion were taking oral BDP up to the
day of endoscopy, but one patient had not taken BDP
for at least 1 month before the endoscopy. One patient
was admitted to the hospital, in part because of diffi-
culty swallowing. Gastrointestinal ulceration or ero-
sion was not associated with other outcomes that
would categorize these events as serious. Ulceration
or erosion was observed in the esophagus (N 5 3),
antrum (N5 1), or both (N5 1). In three of the endos-
copy reports, ulceration or erosion was attributed to
mucositis or esophagitis, and in the other two reports,
no attribution was given. Pathology review showed
GVHD in two cases, nonspecific inflammation in two
cases, and no diagnostic abnormality in one case.
GVHD, bacteremia, and recurrent malignancy
were the most frequent serious adverse events. Other
serious adverse events occurred at frequencies\5%.
The two arms were somewhat imbalanced in the
Biol Blood Marrow Transplant 18:922-929, 2012 927BDP for Prevention of Acute GVHDnumber of serious adverse events related to bacter-
emia, with 14 in the BDP arm and five in the placebo
arm. For this reason, we evaluated the distribution of
all bacteremia episodes. Because participants took
the study drug until day 75 after transplantation and
then stopped, we included all bacteremia episodes
that occurred before day 103. We observed 12 epi-
sodes of Enterococcus bacteremia in 10 of the 92 partic-
ipants in the BDP arm: nine before day 17 after
transplantation and the remaining three after day 57.
We observed a single episode of Enterococcus bacter-
emia among the 46 participants in the placebo arm,
on day 15 after transplantation. In contrast, we ob-
served 15 episodes of gram-negative bacteremia in
the BDP arm, compared with seven in the placebo
arm, which approximates the 2:1 distribution of partic-
ipants between the two arms.
Time-to-first event analyses were used to evaluate
the risks of bacteremia in the BDP arm compared with
the placebo arm. Follow-up was censored at 103 days
after HCT, 28 days after the end of study drug
administration. The hazard ratios were 1.38 (95%
CI, 0.8-2.5) for any bacteremia, 1.32 (95% CI, 0.7-
2.5) for Gram-positive bacteremia, and 5.24 (95%
CI, 0.7-41) for Enterococcus bacteremia. Enterococcus
bacteremia episodes occurred in 10 (nine BDP, one
placebo) of the 61 participants who received TBI be-
fore transplantation and in one (BDP) of the 77 partic-
ipants who received busulfan and cyclophosphamide
before transplantation (P\ .001; Fisher exact test).
The two armswere also somewhat imbalanced in the
number of serious adverse events related to mucositis,
with five in the BDP arm and one in the placebo arm.
For this reason, we evaluated the severity of mucositis
in the two arms for the 118 patients who had evaluations
by an oral medicine specialist on at least one occasion af-
ter transplantation at the Fred Hutchinson Cancer Re-
search Center as part of an independent prospective
study. This analysis did not include participants who en-
rolled in the study at Hackensack University because
these patients did not have evaluations by an oral medi-
cine specialist.Themeanmaximumrecordedoralmuco-
sitis index (OMI) scores [13] were 22.16 14.2 (SD) for
the 79 participants in the BDP arm and 22.76 12.6 for
the 39 participants in the placebo arm (P5 .82; t-test).
Adrenal Function at Day 75 after
Transplantation
Cosyntropin stimulation tests were administered
at approximately 75 days after transplantation in order
to determine whether the level of systemic glucocorti-
coid activity associated with prolonged oral adminis-
tration of BDP was sufficient to decrease adrenal
function in patients who did not receive systemic
glucocorticoid treatment. Abnormal adrenal function
was detected in 26 of the 30 participants (87%) tested
in the BDP arm, compared with five of the eight par-ticipants (63%) tested in the placebo arm (P 5 .12).
Basal cortisol plasma concentrations and the mean
fold-increase in cortisol concentrations at 30 minutes
after cosyntropin stimulation showed no statistically
significant differences between the two arms.
Exploratory Analyses
The lack of apparent efficacy of oral BDP in
preventing aGVHD was unexpected, and adherence
to the study therapy was lower than anticipated. A
number of exploratory analyses were done in an
attempt to clarify these findings and to investigate
whether the two might be associated. Adherence to
the schedule of study drug administration might have
been compromised by mucositis, which is commonly
observed after myeloablative conditioning. Lower
severity of oral mucositis as measured by the
peak OMI score was correlated with increased adher-
ence (Spearman’s correlation coefficient 20.38;
P \ .0001). Adherence was higher in patients who
did not receive systemic treatment for GVHD com-
pared with those who received systemic treatment in
the BDP arm (P 5 .001, t-test) but not in the placebo
arm (P 5 .98), consistent with the possibility that
reduced adherence may have compromised the BDP
treatment effect. Among the 50 BDP patients with
$90% adherence, 27 (54%) had systemic treatment
for GVHD, versus 17 (65%) of the 26 placebo patients
with $90% adherence. The mean cumulative dose
of prednisone before day 75 was 28.8 6 19.6 (SD)
mg/kg among all BDP patients with$90% adherence,
versus 37.1 6 26.6 (SD) mg/kg among all placebo
patients with $90% adherence. In the group with
\90% adherence, the mean cumulative prednisone
dose was the same in both arms (data not shown). As
shown in Figure 3, the cumulative incidence of grades
IIa-IV GVHD (top), grades IIb-IV GVHD (middle),
and grades II-IV GVHD (bottom) in patients catego-
rized according to adherence ($90% versus\90%) is
consistent with the possibility that BDP had a benefi-
cial effect in preventing grade IIa-IV GVHD and
grade IIb-IV GVHD in those with better adherence.
To investigate the potential relationship between
mucositis and response to BDP, we assessed out-
comes in subsets of participants categorized accord-
ing to the peak OMI score above and below the
median. Thirty-nine of the 59 participants (66%)
with peak OMI scores #20 had $90% adherence
with study drug administration, compared with only
23 of the 59 participants (39%) with peak OMI scores
.20. Thirty-seven of the 59 participants (63%) with
peak OMI scores #20 had grades IIa-III GVHD,
compared with 45 of the 59 participants (76%) with
peak OMI scores .20. Nine of the 43 participants
(21%) with peak OMI scores #20 in the BDP arm
had grades IIb-III GVHD, compared with six of
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Adherence >90% Adherence <90%
Figure 3. Cumulative incidence of grades IIa-IVGVHD (top), grades IIb-IVGVHD (middle), and grades III-IVGVHD (bottom) in patients categorized by
adherence.
928 Biol Blood Marrow Transplant 18:922-929, 2012P. J. Martin et al.#20 in the placebo arm. Seven of the 36 participants
(19%) with peak OMI scores .20 in the BDP arm
had grades IIb-III GVHD, compared with six of
the 23 participants (26%) with peak OMI scores
.20 in the placebo arm.DISCUSSION
Results of this study did not support the hypothesis
that prophylactic oral administration of BDPdecreases
the risk of aGVHD as assessed either by the primary
endpoint or by any of the prespecified secondary end-
points. Observations in the two previous randomized
trials where adherence was consistently .90% indi-
cated that oral BDP is effective for treatment of acute
gastrointestinal GVHD [8,9]. Inconsistent study drug
adherence related to mucositis during recovery after
myeloablative conditioning may have obscured
a beneficial therapeutic effect in the current study.
Poor adherence is unlikely to have affected outcomes
among participants in the placebo arm but might
have negated a positive result among those in theBDP arm, particularly with respect to the incidence
of grades IIa-IV and grades IIb-IV GVHD.
The five previous randomized trials evaluating the
effects of prophylactic systemic glucocorticoid admin-
istration after allogeneic bone marrow transplantation
have varied results. The risk of grades II-IV GVHD
was decreased in two studies, unaffected in two, and in-
creased in one [14-18]. The study that showed an
increased risk of grades II-IV GVHD differed from
the others in that administration of methylpredniso-
lone started on the day of transplantation [14]. In the
other studies, steroid administration began on day 7
or 14. It was suggested that steroid administration dur-
ing the first 11 days after transplantation could have
interfered with the GVHD-preventive effects of meth-
otrexate administered on days 1, 3, 6, and 11 after
HCT. Additional results in the same study suggested
that steroid administration beginning on day 15 after
transplantation did not increase the risk of GVHD
but also did not produce any benefit [14].
Although our surveillance of adverse effects in this
study confirmed results of previous studies in showing
Biol Blood Marrow Transplant 18:922-929, 2012 929BDP for Prevention of Acute GVHDthat oral BDP is well tolerated during the first 2 to 3
months after allogeneic hematopoietic cell transplan-
tation, attention to gastric ulceration or erosions and
Enterococcus bacteremia is warranted in future studies.
The number of patients and the frequencies of these
events in the current study were not sufficient to
demonstrate that these adverse events were caused by
BDP. Previous studies did not show an increased risk
of bacteremia associated with the use of systemic
glucocorticoids for prevention of GVHD [14,16-18].
The association of BDP administration with
Enterococcus bacteremia in the current study is not
statistically significant, is clearly data driven, and
could be spurious. We were unable to identify any
previous reports of such an association. All but one
of the Enterococcus bacteremia episodes occurred in
patients who had received TBI, and most of the
episodes occurred during the second and third weeks
after transplantation. Future studies should examine
the possibility that administration of BDP interferes
with protective commensal bacteria or innate defense
mechanisms against Enterococcus species in the
intestinal tract during recovery after TBI.
The double-blind design is a major strength of our
study, but the interpretation of results is hampered by
limited statistical power and by the inability of partic-
ipants to maintain high levels of adherence with oral
ingestion because of mucositis during the first several
weeks after myeloablative conditioning. The study
was designed to evaluate only 138 patients, based on
the anticipation that the effect size would be 25%.
Our results do not rule out the possibility that prophy-
lactic administration of BDPmight provide benefits of
smaller magnitude, or that alternative administration
schedules or testing in patients treated with nonmye-
loablative conditioning regimens before HCT could
demonstrate benefits that were not observed in the
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